Loading…
3 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Davit Tatishvilis Samed… | Healthcare Services | 13.6% | 60th pct | 268 |
| Davit Tatishvilis Janmr… | Healthcare Services | 7.6% | 44th pct | 268 |
| JST Retail | (unclassified) | — | no FY data | 1208 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 2 of 3 peers filed FY2024. Switch to FY2023 (3 of 3).
| Ratio — FY 2024 | Davit Tatishvilis Janmr… | Davit Tatishvilis Samed… | JST Retail |
|---|---|---|---|
| Margins | |||
| Gross Margin | 28.5% | 100.0% | — |
| EBITDA Margin | 7.6% | 13.6% | — |
| EBITDAR | 769 | 810 | — |
| EBITDAR Margin | 14.7% | 24.5% | — |
| EBIT Margin | -0.1% | 11.0% | — |
| Net Profit Margin | -2.9% | 12.1% | — |
| Operating Expense % of Sales | 20.8% | 86.4% | — |
| Returns | |||
| Return on Assets (ROA) | -11.9% | 39.0% | — |
| Return on Equity (ROE) | N/A | 156.3% | — |
| ROIC [EBIT / Invested Capital] | -0.9% | 107.1% | — |
| Leverage & debt balances | |||
| Debt-to-Assets | 142.9% | 8.7% | — |
| Debt-to-Equity | -1.62x | 0.35x | — |
| Debt-to-EBITDA | 4.50x | 0.20x | — |
| Equity-to-Assets | -88.2% | 25.0% | — |
| Net Debt | 1,790 | 84 | — |
| Cash & Equivalents | 8 | 5 | — |
| Total Debt | 1,798 | 90 | — |
| Liquidity & working capital | |||
| Current Ratio | 0.19x | 0.36x | — |
| Quick Ratio | 0.19x | 0.36x | — |
| Cash Ratio | 0.00x | 0.01x | — |
| Total Current Assets | 440 | 164 | — |
| Total Current Liabilities | 2,307 | 453 | — |
| Inventory | N/A | N/A | — |
| Trade Receivables | 397 | 135 | — |
| Trade Payables | 319 | 453 | — |
| Net Working Capital | -1,867 | -289 | — |
| Net Working Capital % of Revenue | -35.7% | -8.8% | — |
| Trade Working Capital | 79 | -318 | — |
| Trade Working Capital % of Revenue | 1.5% | -9.6% | — |
| Change in Trade Working Capital | N/A | N/A | — |
| Turnover & efficiency | |||
| Inventory Turnover | N/A | N/A | — |
| Days Inventory Outstanding (DIO) | N/A | N/A | — |
| Receivables Turnover | 13.17x | 24.41x | — |
| Days Sales Outstanding (DSO) | 27.7 | 15.0 | — |
| Payables Turnover | 11.76x | N/A | — |
| Days Payable Outstanding (DPO) | 31.0 | N/A | — |
| Cash Conversion Cycle | -3.3 days | 15.0 days | — |
| Asset Turnover | 4.16x | 3.22x | — |
| Cash flow & dividends | |||
| Operating Cash Flow | 6 | N/A | — |
| Free Cash Flow (OCF − Capex proxy) | 6 | N/A | — |
| Cash Conversion (OCF / EBITDA) | 1.5% | N/A | — |
| Dividends Declared | N/A | N/A | — |
| Dividend Payout Ratio | N/A | N/A | — |